MORINDA COREIA HAS AN ANTI-HELICOBACTER PYLORI EFFECT AGAINST THE MULTIDRUG-RESISTANT CLINICAL ISOLATE OF NORTH-EAST INDIA

Authors

  • Shweta Mahant Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
  • Valentina Gehlot Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
  • Shanu Hoda Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
  • Pooja Vijayaraghavan Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
  • Selvamurthy W Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.
  • Thirumurthy N BT Herbal, Sivakasi, Tamil Nadu, India.
  • Rajashree Das Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i12.28064

Keywords:

Helicobacter pylori, Morinda coreia, Resistance, Antibiogram

Abstract

Objective: Antimicrobial resistance is a growing problem in Helicobacter pylori eradication which is a microaerophilic bacterium causing various gastroduodenal diseases. The present study has been designed to test the efficacy of Morinda coreia against the metronidazole clarithromycin and levofloxacin-resistant H. pylori strains isolated from the biopsy taken from the patient suffering from gastric erosion in Guwahati, Assam.

Method: The antimicrobial activity of n-hexane and chloroform extract of M. coreia was tested against multidrug-resistant H. pylori isolate of Guwahati, Assam, by agar well method and microdilution method.

Result: In the present study, the H. pylori strain resistant for metronidazole (minimal inhibitory concentration [MIC] >64 μg/mL), clarithromycin at (MIC >0.5 μg/mL), and levofloxacin at (MIC >1 μg/mL) was tested against the n-hexane and chloroform extract of M. coreia. Both the extracts of M. coreia showed good efficacy against the multidrug-resistant strain of H. pylori shown inhibition at 1.2 μg/mL with n-hexane extract and 2 μg/mL with chloroform extract of M. coreia.

Conclusion: The prevalence of metronidazole-resistant ranges between 50% and 90% in the developing countries, including India, clarithromycin ranges from 0% to 15% in India, and levofloxacin ranges between 50% and 70% in India, so there is a need of alternative therapy for the eradication of this bacterium from the stomach. Hence, this study suggests that M. coreia, which has been used traditionally as a folk medicine for the treatment of many gastric diseases, has also shown good efficacy against the multidrug-resistant H. pylori strain of North-east India.

Downloads

Download data is not yet available.

Author Biographies

Shweta Mahant, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.

Assistant Professor, Amity Institute of Biotechnology, Amity University, Noida.

Valentina Gehlot, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.

Ph. D scholar, Amity Institute of Biotechnology, Amity University, Noida.

Shanu Hoda, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.

Professor, Amity Institute of Biotechnology, Amity University, Noida.

Pooja Vijayaraghavan, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.

Present, Amity Science, Technology & Innovation Foundation, Amity University, Noida, Uttar Pradesh

Selvamurthy W, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.

BT Herbal, Sivakasi, Tamil Nadu

Thirumurthy N, BT Herbal, Sivakasi, Tamil Nadu, India.

Research Assistant, Amity Institute of Biotechnology, Amity University, Noida.

Rajashree Das, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India.

Associate Professor, Amity Institute of Biotechnology, Amity University, Noida.

References

Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol 1997;10:720-41.

Blaser MJ. Epidemiology and pathophysiology of Campylobacter pylori infections. Infect Dis 1990;12 Suppl 1:S99-106.

Matthews GM, Butler RN. Cellular mucosal defense during Helicobacter pylori infection: A review of the role of glutathione and oxidative pentose pathway. Helicobacter 2005;10:298-306.

Montecucco C, Rappuoli R. Living dangerously: How Helicobacter pylori survive in the human stomach. Nat Rev Mol Cell Biol 2001;2:457-66.

Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1639-43.

Bytzer P, O’Morain C. Treatment of Helicobacter pylori. Helicobacter 2005;10:40-6.

Cameron EA, Powell KU, Baldwin L, Jones P, Bell GD, Williams SG, et al. Helicobacter pylori: Antibiotic resistance and eradication rates in suffolk, UK, 1991-2001. J Med Microbiol 2004;53:535-8.

Datta S, Chattopadhyay S, Patra R, De R, Ramamurthy T, Hembram J, et al. Most Helicobacter pylori strains of Kolkatta in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther 2005;22:51-7.

Das R, Gehlot V, Mahant S, Mukhopadhyay AK, Das K. High prevalence of single, dual, and multidrug resistant Helicobacter pylori infection in India. Helicobacter 2015;20 Suppl 1:P03.18.

Miyazi H, Azuma T, Ito S, Suto H, Ito Y, Yamazaki Y. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxicillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997;11:1131-6.

Kiritikar KR, Basu BD. Indian Medicinal Plants. 3rd ed. Allahabad: Lalit Mohan Basu MB; 1996. p. 2757.

Singh J, Tiwari RD. Flavone glycosides from the flowers of Morinda species. J Ind Chem Soc 1976;53:424.

Matthew KM. The Flora of the Tamilnadu Carnatic. Tiruchirappalli: The Rapinat Herbarium, St. Joseph’s College; 1983. p. 1-3, 718.

Kantachote D, Kowpong K, Charernjiratrakul W, Pengoo A. The possibilities of using the fruit of Morinda coreia to make a liquid manure. Electron J Biotechnol 2009;12:1-11.

Antonysamy K, Soosai S, Sebastin S, Prakasam R. Biosynthesis of silver nanoparticles from Morinda Coreia Buch.-Ham. And it’s antibacterial activity. Int J Pharm Sci Res 2014;5:5321-7.

Andrews JM. BSAC working party on susceptibility testing. BSAC standardized disc susceptibility testing method. J Antimicrob Chemother 2005;56:60-76.

Clinical Laboratory Standard Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline. 2nd ed. CLSI document M45-A2. Vol. 30. No. 18. Wayne, PA, USA: CLSI; 2010.

EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 3.1. EUCAST; 2013.

Murray MG, Thompson WF. Rapid isolation of high molecular weight plant DNA. Nucleic Acid Res 1980;8:4321-5.

Garrido L, Toledo H. Novel genotypes in Helicobacter pylori involving domain V of the 23S rRNAgene. Helicobacter 2007;12:505-9.

Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995;39:107-11.

Jeong JY, Mukhopadhyay AK, Dailidiene D, Wang Y, Velapatino B, Gilman RH, et al. Sequential Inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori. J Bacteriol 2000;182:5082-90.

Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol 2003;18:1373-8.

Gehlot V, Mahant S, Mukhopadhyay AK, Das K, De R, Kar P, et al. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from the patients in North India. J Glob Antimicrob Resist 2015;5:51-6.

Singh V, Mishra S, Maurya P, Rao G, Jain AK, Dixit VK, et al. Drug resistance pattern and clonality in H. pylori strains. J Infect Dev Ctries 2009;3:130-6.

Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J Med Microbiol 2014;32:408-13.

Rasheed F, Campbell BJ, Alfizah H, Varro A, Zahra R, Yamaoka Y, et al. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. Helicobacter 2014;19:387-99.

Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, et al. Primary antibiotic resistance in Helicobacter pylori in the asia-pacific region: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2017;2:707-15.

Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82.

Gehlot V, Mahant S, Das R. Most of the Helicobacter pylori isolates are resistant to levofloxacin in North India. Int J Pharm Pharm Sci 2016;8:454-6.

Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P, et al. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in north india. J Glob Antimicrob Resist 2016;6:39-43.

Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol 2015;5:164-74.

De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother 2009;53:1592-7.

Chanda S, Gehlot V, Das R, Mahant S, Das K, Singh K, et al. Antimicrobial activity of herbal extract against drug resistant Helicobacter pylori isolates from India. World J Pharm Res 2014;3:1234-43.

Gehlot V, Mahant S, Vijayraghwan P, Das K, Hoda S, Das R. Therapeutic potential of lichen Parmelia perlata against dual drug-resistant Helicobacter pylori isolates. Int J Pharm Pharm Sci 2015;8:205-8.

Mehrotra S, Jamwal R, Shyam R, Meena DK, Mishra K, Patra R, et al. Anti-Helicobacter pylori and antioxidant properties of Emblica officinalis pulp extract: A potential source for therapeutic use against gastric ulcer. J Med Plants Res 2011;5:2577-83.

Mahant S, Gehlot V, Bhatnagar S, Rikhi M, Mukhopadhyay AK, Dutta S, et al. Antibiogram profiling of Helicobacter pylori strains and the efficacy of Brassica capitata against resistant strains isolated from the patients suffering from gastroduodenal diseases in Gauhati, Assam. Asian J Pharm Clin Res 2018;11:176-80. (In Press).

Wang MY, West BJ, Jensen CJ, Nowicki D, Su C, Palu AK, et al. Morinda citrifolia (Noni): A literature review and recent advances in noni research. Acta Pharmacol 2002;12:1127-41.

Published

07-12-2018

How to Cite

Mahant, S., V. Gehlot, S. Hoda, P. Vijayaraghavan, S. W, T. N, and R. Das. “MORINDA COREIA HAS AN ANTI-HELICOBACTER PYLORI EFFECT AGAINST THE MULTIDRUG-RESISTANT CLINICAL ISOLATE OF NORTH-EAST INDIA”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 12, Dec. 2018, pp. 143-8, doi:10.22159/ajpcr.2018.v11i12.28064.

Issue

Section

Original Article(s)